In the evolving fi TFLLR-NH2, PAR1 agonist peptide (CAS 197794-83-5) eld of biochemical research, the study of G-protein coupled receptors (GPCRs) has opened new doors for understanding cellular signaling. Among these, the PAR1 peptide stands out as a critical tool for investigators exploring the intricate mechanisms of the thrombin receptor. As someone who follows advancements in peptide An optimized agonist peptide of protease-activated science, I have found the structural and functional nuances of these molecules to be both fascinating and high Molecular mechanisms regulating Proteinase‐Activated ly technical.
Defining the PAR1 Landscape
The Protease activated receptor 1 (PAR-1) is a member of a unique subfamily of GPCRs. It is fundamentally important because PAR1 plays a key role in mediating the interplay between coagulation and inflammation at the cellular level. Unlike standard receptors that require a traditional ligand to bind, PAR1 is transiently activated by thrombin, which cleaves the receptor, revealing a new N-terminus that acts as a "tethered ligand."
When researchers utilize a PAR1 agonist peptide, they are essentially bypassing the need for protease cleavage to initiate signaling. This provides a controlled environment to study how the receptor functions independently of enzymatic activity.
Technical Specifications and Variations
For those involved in laboratory analysis, the specificity of the reagent is paramount. For instance, the well-known TFLLR-NH2 is a standard PAR1 agonist peptide with a molecular weight of 647.8 Da and a purity >95%. Achieving reliable results requires working with compounds that meet these high-quality benchmarks.
My experience with these peptides highlights the following technical attributes:
* Biased Signaling: PAR1 is a biased 7-transmembrane receptor. Depending on the stimulus, it can couple to various G-proteins, including Gi, Gq, and G12/13 subfamilies.
* Structural Requirements: Research indicates that PAR1 activating peptides require specific L-amino acids and amide protons for optimal binding affinity. Par-1 selective activating peptide
* Functional Diversity: While the standard agonist mimics thrombin, other variants, such as the PAR1 agonist peptide AP9, have demonstrated protective properties in vivo, highlighting the versatility of these sequences.
Investigating Biological Interactions
The significance of these peptides extends to their ability to modulate cellular pathways. For example, a protease-activated receptor-1 (PAR-1) selective peptide is frequently used to induce cyclooxygenase-2 (COX-2) protein and mRNA expression in human endothelial cells. Furthermore, studies have shown that a peptide-agonist of protease-activated receptor (PAR1) stimulates keratinocyte proliferation and epithelial layer wound healing, providing a model for examining tissue repair proce PAR1: Small Molecules and Peptides sses.
Interestingly, the signaling landscape is further complicated by receptor dimerization. We know that PAR3 dimerization with PAR1 changes the selectivity of PAR1 to Gα13, t Protease-Activated Receptor-1, PAR-1 Agonist hereby enhancing Gα13-mediated signaling. This cross-talk suggests that the PAR1 agonist is just one piece of a larger, more complex puzzle involving the F by Z Lyu·2025·Cited by 14—ComprisingPAR1-PAR4, these receptors are specifically activated by protease cleavage at their extracellular amino terminus, revealing a ' Read more 2R gene and its regulatory partners.
Practical Considerations for Research
When discussing the Protease-Activated Receptor-1, PAR-1 Agonist, one must consider the historical context of TR(1-41), the cleaved peptide of PAR1, which remains a potent stimulant in various assays. Whether you are using a par-1 selective activating pep by DE Zampatis·2012·Cited by 30—The protease-activated receptor 1 (PAR1) is activated by thrombin cleavage releasing the physiologically-relevant parstatinpeptideRead more tide for high-throughput screening or investigating the biased agonism mediated by activated protein C (APC) and certain PAR1- and PAR3-derived peptides, the focus remains on the precision of the interaction.
In my view, the most compelling aspect of current research is how PAR1 mediates all thrombin-induced phosphoregulation in ECs. By utilizing a synthetic PAR1 agonist peptide, scientists can isolate these pathways, effectively acting as a thrombin receptor activator without the unpredictable nature of endogenous proteases.
As we look toward the future, the continued refinement of these peptides will undoubtedly provide deeper insights into the fundamental biology of membrane receptors. Whether the goal is to understand G-protein coupling or to map the downstream effects of receptor activation, the PAR1 peptide remains an indispensable asset in the biochemist’s toolkit.